ACTIVE_NOT_RECRUITING

A Study of LY3841136 in Overweight and Obese Participants

Description

The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.

Conditions

ObesityOverweight
Talk to us

Related Conditions:

ObesityOverweight

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.

A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants

A Study of LY3841136 in Overweight and Obese Participants

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Daytona Beach

Fortrea Clinical Research Unit, Daytona Beach, Florida, United States, 32117

Dallas

Fortrea Clinical Research Unit, Dallas, Texas, United States, 75247

Madison

Fortrea Clinical Research Unit, Madison, Wisconsin, United States, 53704

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male and female participants who are overtly healthy as determined by medical evaluation
  • * Have a stable body weight and Body Mass Index in range of 27 to 45 kilogram per meter square (kg/m²).
  • * Have clinical laboratory test results within normal reference range
  • * Have venous access sufficient to allow for blood sampling
  • * Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • * Have type 1 or type 2 diabetes mellitus
  • * Have an abnormal 12-lead electrocardiogram (ECG)
  • * Have a history or presence of psychiatric disorders
  • * Have abnormal blood pressure and pulse rate
  • * Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product.

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2025-10